Pancreatic neoplasm
Therapeutic area
Endocrinology
Rare disease
No
- Definition
- A benign or malignant neoplasm involving the pancreas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pancreatic neoplasm
- Therapeutic area
- Endocrinology
- pancreatic neoplasm
- neoplasm of pancreas
- neoplasm of the pancreas
- pancreas neoplasm
- pancreas neoplasm (disease)
- pancreas tumor
- pancreas tumour
- pancreatic neoplasm
- pancreatic tumor
- pancreatic tumour
- tumor of pancreas
- tumor of the pancreas
- tumour of pancreas
- tumour of the pancreas
- pancreas
- Severity
- Unknown
- Endocrinology
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0021040
- Parent condition
- MONDO:0002356
Related records
Broader conditions (11)
- Cancer or benign tumor
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine system disorder
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Pancreas disorder
Narrower conditions (71)
- Adenoma of pancreas
- Benign neoplasm of exocrine pancreas
- Benign neoplasm of pancreas
- Colloid carcinoma of the pancreas
- Cystic tumor of the pancreas
- Enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor
- Exocrine pancreatic carcinoma
- Familial pancreatic carcinoma
- Functional pancreatic neuroendocrine tumor
- GCGR-related hyperglucagonemia
- Glucagonoma
- GRFoma
- Intraductal tubulopapillary neoplasm of pancreas
- Malignant exocrine pancreas neoplasm
- Malignant pancreatic neoplasm
- Mixed ductal-endocrine carcinoma of pancreas
- Mucinous pancreas adenocarcinoma
- Non-functional pancreatic neuroendocrine tumor
- Pancreas lymphoma
- Pancreas sarcoma
Trials (3,742)
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
- "Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- [68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer
- [Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers
- 131-I-TM-601 Study in Adults With Solid Tumors
- 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
- 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
- 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
- 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 22 G - 25 G SINS Trial for Pancreatic Masses
- 22G FNA Needle vs. 22G ProCore Needle
- 22G-Adapt Needle Biopsy Versus Fine-needle Aspiration in Endoscopic Ultrasound-guided Sampling of Solid Lesions
- 22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 25G and 22G Puncture Needles
Approved drugs (6)
- Erlotinib hydrochloride
- Everolimus
- Irinotecan hydrochloride
- Olaparib
- Paclitaxel
- Zenocutuzumab
Drugs in development (135)
- ABGN-107 Phase 1
- Adebrelimab Phase 2
- Adenosine diphosphate Phase 1
- Alectinib Phase 2
- Algenpantucel-L Phase 3
- Antroquinonol Phase 1
- Apricoxib Phase 2
- Archexin Phase 2
- Aroplatin Phase 1
- Ascorbic acid Phase 2
- ASG-5ME Phase 1
- Atezolizumab Phase 1
- Axitinib Phase 2
- Bevacizumab Phase 3
- BI-2536 Phase 2
- Bintrafusp alfa Phase 1
- Bupivacaine Phase 3
- Cabiralizumab Phase 2
- Cadonilimab Phase 2
- Capecitabine Phase 3
Other linked drugs (22)
- Aglatimagene besadenovec
- Anamorelin hydrochloride
- AR-20.5
- Avasopasem manganese
- Bentiromide
- Brivudine
- Defactinib
- Ibrilatazar
- Losartan
- Nivolumab
- Pelareorep
- Racemetyrosine
- Rubitecan
- Salirasib
- Secretin synthetic human
- Selpercatinib
- Streptozocin
- Tipifarnib
- Tisagenlecleucel
- Tricaprilin